The impact of changes in fibromyalgia diagnosis criteria: using NAMCS data (2010–2019) to identify trends

BMC Rheumatology

Table 1 Demographic and participant visit characteristics

Characteristic	Weighted frequency^a (%) of visits N = 248,164^b
BMI (mean ± SE)	29.2 ± 0.09
Gender
Female Male	472,014,489 (60.2) 311,513,220 (39.8)
Race
Non-White White	95,835,452 (16.6) 481,506,931 (83.4)
Ethnicity
Hispanic or Latino Not Hispanic or Latino	72,693,777 (12.3) 516,320,589 (87.7)
Urbanicity
Urban (MSA) Rural (non-MSA)	712,139,567 (90.9) 71,388,142 ( 9.1)
Specialty
Medical Care Surgical Care Primary Care	231,355,616 (29.5) 176,986,577 (22.6) 375,185,516 (47.9)
Diabetes
Yes No	119,626,482 (15.3) 663,901,227 (84.7)
Depressive Disorder
Yes No	90,164,943 (11.5) 693,362,766 (88.5)
Generalized Anxiety Disorder
Yes No	25,758,024 ( 3.3) 757,769,685 (96.7)
Malaise / Fatigue
Yes No	8,997,102 ( 1.1) 774,530,607 (98.9)
Rheumatoid Arthritis
Yes No	4,795,425 ( 0.6) 778,732,284 (99.4)
Lupus^c
Yes No	1,742,762 ( 0.2) 781,784,947 (99.8)
Irritable Bowel Syndrome^c
Yes No	2,216,384 ( 0.3) 781,311,325 (99.7)
Cognitive Function Symptoms^c
Yes No	552,357 ( 0.1) 782,975,353 (99.9)
Sleep Disorder^c
Yes No	4,023,448 ( 0.5) 779,504,261 (99.5)
Soft Tissue Disorder
Yes No	4,435,393 ( 0.6) 779,092,316 (99.4)
Cramps / Spasms^c
Yes No	696,976 ( 0.1) 782,830,733 (99.9)
Weight Gain^c
Yes No	7,227,339 ( 0.9) 776,300,370 (99.1)
Stomach Pain^c
Yes No	3,905,686 ( 0.5) 779,622,023 (99.5)
Nausea^c
Yes No	5,736,626 ( 0.7) 777,791,083 (99.3)
Diarrhea^c
Yes No	5,763,434 ( 0.7) 777,764,275 (99.3)
Itching^c
Yes No	88,488 ( <0.1) 783,439,221 (> 99.9)
Fibromyalgia
Yes No	5,206,059 (0.7) 778,321,650 (99.3)

^a Survey weighting, stratification, and clustering accounted for reflecting unbiased, national annual estimates of visit occurrences for the portion of the population meeting the study inclusion and exclusion criteria
^b Out of the 1,659 survey visits as which fibromyalgia was diagnosed, IBS (n = 17; Relative Standard Error [RSE] = 32%) and lupus (n = 25; RSE = 35%) and general anxiety disorder (RSE = 35%) were either reported at less than 30 visits and/or had a RSE > 30%. Per the NCHS, the estimate for these variables in this table are potentially unreliable due to the small count (and/or elevated RSE value). Caution is urged in interpreting this estimate
^c Out of the 1,659 survey visits as which fibromyalgia was diagnosed, sleep disorder, cognitive function symptoms, cramps/spasms, weight gain, stomach pain, nausea, diarrhea and itching was reported at less than 15 visits. Per the NCHS, these estimates are entirely unreliable and thus not reported in this table even though the variables were included in the model

ISSN: 2520-1026